Evaxion Biotech A/S (EVAX) has a consensus analyst rating of Buy, based on 4 analysts covering the stock. Of those, 4 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for EVAX is $10.50, representing a +153.6% upside from the current price of $4.14. Price targets range from a low of $10.00 to a high of $11.00.
